hormone receptor-positive/HER2-negative breast cancer
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0070780
Name hormone receptor-positive/HER2-negative breast cancer
Definition A HER2 negative breast cancer characterized by at least one of the estrogen or progesterone receptors and the absence of HER2 (EBBR2) protein.
Source DiseaseOntology.org
Alt Ids
Xrefs
Path disease disease of cellular proliferation cancer organ system cancer breast cancer HER2 negative breast cancer hormone receptor-positive/HER2-negative breast cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04557449 Phase Ib/II Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 + Tamoxifen Giredestrant + PF-07220060 Enzalutamide + PF-07220060 PF-07220060 Midazolam + PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Recruiting USA | SVK | GBR | CZE | ARG 3
NCT07748208 Phase II Fulvestrant + Inavolisib + Palbociclib A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes Recruiting USA 1